ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.

CADL Candel Therapeutics Inc

9.33
0.48 (5.42%)
최종 업데이트: 02:43:15
15분 지연
기업명 주식 심볼 시장 주식 타입
Candel Therapeutics Inc CADL 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
0.48 5.42% 9.33 02:43:15
개장가 저가 고가 종가 전일 종가
9.00 8.66 9.6299 8.85
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
25/04/202421:00GLOBECandel Therapeutics Announces Upcoming Presentations at the..
11/04/202422:00GLOBECandel Therapeutics Receives FDA Orphan Drug Designation for..
09/04/202421:00GLOBECandel Therapeutics Presents Preclinical Data at AACR on..
04/04/202421:00GLOBECandel Therapeutics Announces Positive Interim Data from..
29/03/202405:05GLOBECandel Therapeutics Announces Oral Presentation During the..
28/03/202421:05GLOBECandel Therapeutics Reports Fourth Quarter and Full Year..
06/03/202422:00EDGAR2Form 8-K - Current report
06/03/202406:30GLOBECandel Therapeutics Announces an Upcoming Presentation at..
13/02/202423:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/02/202421:45EDGAR2Form 8-K - Current report
13/02/202421:30GLOBECAN-3110 Receives FDA Fast Track Designation for Treatment..
05/02/202422:00GLOBECandel Therapeutics Sets Path to Success: Recent..
19/01/202422:30EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/01/202406:30EDGAR2Form 8-K - Current report
03/01/202422:30EDGAR2Form 8-K - Current report
12/12/202322:58DJNCandel Therapeutics Shares Soar After FDA Fast Track of..
12/12/202322:30EDGAR2Form 8-K - Current report
12/12/202322:00GLOBECandel Therapeutics Receives FDA Fast Track Designation for..
01/12/202307:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202307:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202307:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202306:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202306:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202306:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202323:00EDGAR2Form 8-K - Current report
28/11/202323:00GLOBECandel Therapeutics Announces Restructuring to Prioritize..
22/11/202307:00EDGAR2Form 8-K - Current report
09/11/202322:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:16EDGAR2Form 8-K - Current report
09/11/202322:00GLOBECandel Therapeutics Reports Third Quarter 2023 Financial..
06/11/202322:53EDGAR2Form 8-K - Current report
06/11/202322:15EDGAR2Form 8-K - Current report
04/11/202321:00GLOBECandel Therapeutics Presents Preclinical Data from its..
04/11/202301:00GLOBECandel Therapeutics Announces Initial Positive Interim Data..
19/10/202300:31EDGAR2Form 8-K - Current report
19/10/202300:00GLOBECandel Therapeutics Announces Nature Publication Showing..
27/09/202322:40GLOBECandel Therapeutics Announces Three Abstracts Accepted for..
26/09/202321:30EDGAR2Form 8-K - Current report
26/09/202321:00GLOBECandel Therapeutics Reports Encouraging Initial Survival..
06/09/202321:00GLOBECandel Therapeutics to Participate in the H.C. Wainwright..
10/08/202321:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/08/202321:15EDGAR2Form 8-K - Current report
10/08/202321:00GLOBECandel Therapeutics Reports Second Quarter 2023 Financial..
02/08/202321:00GLOBECandel Therapeutics to Participate in the Canaccord Genuity..
29/06/202322:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/06/202322:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/06/202322:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/06/202321:31EDGAR2Form 8-K - Current report
13/06/202321:00GLOBECandel Therapeutics Announces It Expects to Report Topline..
08/06/202321:00GLOBECandel Therapeutics Appoints Experienced Manufacturing..

최근 히스토리

Delayed Upgrade Clock